Class action against BioMimetic dismissed

The leaders of BioMimetic Therapeutics have one fewer legal headache to be concerned about: A District Court judge last week tossed a purported class action against the company, CEO Sam Lynch and CFO Larry Bullock. Plaintiffs had filed their complaint in the summer of 2011, saying Lynch and Bullock had violated securities rules in making statements about the progress of BioMimetic's Augment bone graft treatment.